Clinical trials: Radiation Therapy Patient
Solid Tumour Neoplastic Meningitis, Brain Metastases
Study to Demonstrate the Safety of WBR Administered at the Same Time as Intrathecal Liposomal Cytarabine (DepoCyte®) Versus Intrathecal Liposomal Cytarabine (DepoCyte®) Administered After WBR for the Treatment of Solid Tumour Neoplastic Meningitis in Patients With or Without Brain Metastasis.
The purpose of this study is to demonstrate the safety of giving Whole Brain Radiotherapy (WBRT) together with intrathecal liposomal cytarabine (DepoCyte®) for patients with leptomeningeal metastases.
- Trial name
- NCT00854867
- Testing
- Whole Brain Radio Therapy (WBRT) with sequential Depocyte, Whole brain radiotherapy (WBRT) with concomitant Depocyte
- Where
- 7 sites in Austria, Germany
- Volunteers
- 18 people
- Sponsor
- Mundipharma Research Limited
Alopecia; X-Rays
Radiation- Induced Alopecia in Patients Undergoing Radiation Therapy to the Brain
Study will be conducted on patients receiving Whole brain(WB) / Partial Brain(PB) radiotherapy using volumetric modulated arc therapy or intensity modulated radiotherapy at Department of Radiation Oncology, Fortis Memorial…
- Trial name
- NCT03543020
- Testing
- radiation therapy to brain
- Where
- India
- Volunteers
- 25 people
- Sponsor
- Fortis Memorial Research Institute
Prostate Adenocarcinoma
Bicalutamide Implants (Biolen) With Radiation Therapy in Patients With Localized Prostate Cancer
This study will be undertaken to evaluate the feasibility of replacing systemic Androgen Deprivation Therapy (ADT) with targeted local delivery of an anti-androgen agent alone in patients in whom ADT + radiation therapy is…
- Trial name
- BiolenRT (NCT04943536)
- Testing
- bicalutamide, Stereotactic body radiation therapy
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Alessa Therapeutics Inc.
Alzheimer Disease
Exploratory Study of Low-Dose Whole-Brain Radiation Therapy With HeLaXON 1X in Patients With Mild Alzheimer's Disease Dementia
This randomized, sham-controlled, exploratory clinical trial will evaluate the efficacy and safety of HeLaXON, an investigational low-dose radiation therapy device, in patients with mild Alzheimer's disease dementia.
- Trial name
- LDRT-AD-03 (NCT07863011)
- Testing
- HeLaXON 1X Low-Dose Radiation Therapy
- Where
- South Korea
- Volunteers
- 30 people
- Sponsor
- ReadyCure Inc.
Colorectal Cancer, GPA33
Phase IIT Trial of SNA009
This clinical trial is a single-center, open-label, dose-escalation study designed to evaluate the safety, tolerability, pharmacokinetics and radiation dosimetry of 68Ga-NODAGA-SNA009 in patients with colorectal cancer.
- Trial name
- NCT07597759
- Testing
- 68Ga-NODAGA-SNA009
- Where
- China
- Volunteers
- 12 people
- Sponsor
- SmartNuclide Biopharma
High Grade Glioma
Trans Sodium Crocetinate (TSC) Study of Intra-tumoral Oxygen Concentration, Safety, and Pharmacokinetics in Patients With High Grade Glioma
The purpose of this study is to evaluate the impact of Trans Sodium Crocetinate (TSC) on oxygen levels in brain tumor tissue in patients with high grade glioma.
- Trial name
- NCT00826930
- Testing
- Trans Sodium Crocetinate (TSC)
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Diffusion Pharmaceuticals Inc
Head and Neck Neoplasms
Pharmacokinetic Study of Porfiromycin in Head and Neck Cancer and Other Cancer Patients With Solid Tumors
Study to determine the steady-state pharmacokinetics and urinary excretion of porfiromycin and major metabolites in head and neck cancer and other cancer patients with solid tumors who receive radiation therapy.
- Trial name
- NCT02209701
- Testing
- Porfiromycin
- Volunteers
- 3 people
- Sponsor
- Boehringer Ingelheim
Glioblastoma (GBM)
A Phase 1/2 Study of the Safety and Tolerability of MT-125 in GBM Patients
The purpose of the study is to determine the recommended dose and further understand the safety of MT-125 in participants who have been diagnosed with glioblastoma, a primary brain tumor, when administered in combination with…
- Trial name
- STAR-GBM (NCT07185880)
- Testing
- MT-125
- Where
- 3 sites in United States
- Volunteers
- 36 people
- Sponsor
- Myosin Therapeutics Inc.
Non-small Cell Lung Cancer (NSCLC)
Investigate the Maximum Tolerated Dose of Vandetanib and Concurrent Whole Brain Radiotherapy (WBRT) in Patients With Non-small Cell Lung Cancer (NSCLC) and Brain Metastases
A clinical study to investigate the maximum tolerated dose of Vandetanib and concurrent WBRT in patients with NSCLC and brain metastases. All patients will receive WBRT, 10 fractions of 3 Gy.
- Trial name
- NCT00807170
- Testing
- ZD6474 (Vandetanib), Whole Brain Radiotherapy (WBRT), ZD6474
- Where
- 3 sites in Netherlands
- Volunteers
- 5 people
- Sponsor
- Sanofi
AMD, Wet AMD
INTREPID - IRay Plus Anti-VEGF Treatment For Patients With Wet AMD
The purpose of this study is to confirm the safety and establish the effectiveness of two doses from the IRay System for the treatment of wet AMD.
- Conditions
- AMD, Wet AMD, Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration
- Trial name
- INTREPID (NCT01016873)
- Testing
- IRay
- Where
- 21 sites in Austria, Czechia and 3 more
- Volunteers
- 230 people
- Sponsor
- Oraya Therapeutics, Inc.
Prostate Cancer
External Beam Therapy With Theranostic Radioligand Therapy for Oligometastatic Prostate Cancer (ProstACT TARGET)
This is a phase II trial to evaluate the therapeutic efficacy of a radiolabelled PSMA-targeting antibody, 177Lu-TLX591, given in combination with external beam radiation therapy (EBRT) in patients with biochemically recurrent…
- Trial name
- NCT05146973
- Testing
- 177Lu-DOTA-TLX591
- Where
- 4 sites in Australia
- Volunteers
- 5 people
- Sponsor
- Telix Pharmaceuticals (Innovations) Pty Limited
Prostate Cancer
Study to Assess the Efficacy of Brachytherapy With or Without Hormone Therapy, Using Triptorelin 22.5mg in Patients With Recurrence of Prostate Cancer
The primary objective of the study was to compare the efficacy of brachytherapy versus brachytherapy + triptorelin 22.5 mg (single injection) in subjects with recurrence of prostate cancer previously treated with radiotherapy.
- Trial name
- ANABRAQ (NCT01374087)
- Testing
- Triptorelin 22.5 mg, Brachytherapy
- Where
- 11 sites in Spain
- Volunteers
- 32 people
- Sponsor
- Ipsen
Glioblastoma, GBM
Safety and Efficacy of Trans Sodium Crocetinate (TSC) With Radiation and Temozolomide in Newly Diagnosed Glioblastoma
This open-label study evaluated the safety and efficacy of TSC when dosed concomitantly with the standard of care (radiation therapy and temozolomide) for newly diagnosed glioblastoma in adults.
- Conditions
- Glioblastoma, GBM, Glioma
- Trial name
- NCT01465347
- Testing
- Trans Sodium Crocetinate (TSC)
- Where
- 18 sites in United States
- Volunteers
- 59 people
- Sponsor
- Diffusion Pharmaceuticals Inc
Brain Metastases From Solid Tumors
131I-L19SIP Radioimmunotherapy (RIT) in Combination With External Beam Radiation in Patients With Multiple Brain Metastases From Solid Tumors
The aim of this Proof of Concept study is to determine the therapeutic potential of the L19SIP antibody, labeled with the radionuclide 131I in combination with external beam radiation, for the treatment of patients with multiple…
- Trial name
- NCT01125085
- Testing
- 131I-L19SIP Radioimmunotherapy (RIT) in Combination With Whole Brain Radiation Therapy (WBRT)
- Where
- 10 sites in Italy, United Kingdom
- Volunteers
- 32 people
- Sponsor
- Philogen S.p.A.
Healthy Volunteers, Pancreatic Ductal Adenocarcinoma
Safety of RAD301 in Healthy Human Volunteers and Patients With Pancreatic Cancer or Other Solid Tumors
This is a Phase 1a, open label, single dose, extended study of safety and biokinetics of RAD301 in healthy human volunteers and individuals with PDAC or Other Solid Tumors
- Conditions
- Healthy Volunteers, Pancreatic Ductal Adenocarcinoma, Non-small Cell Lung Cancer (NSCLC), Esophageal Squamous Cell Carcinoma
- Trial name
- RAD301 (NCT05799274)
- Testing
- RAD301 ([68Ga]-RAD301)
- Where
- 2 sites in United States
- Volunteers
- 9 people, healthy volunteers welcome
- Sponsor
- Radiopharm Theranostics, Ltd
Lung Cancer
ZD6474 in Treating Patients With Small Cell Lung Cancer
RATIONALE: ZD6474 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. ZD6474 may also stop the growth of small cell lung cancer by blocking blood flow to the tumor.
- Trial name
- NCT00066313
- Testing
- vandetanib, adjuvant therapy
- Where
- 21 sites in Canada
- Sponsor
- Genzyme, a Sanofi Company
Oral Mucositis (Ulcerative), Oral Mucositis (Ulcerative) Due to Radiation
Photobiomodulation to Demonstrate Safety and Reduce the Incidence of Oral Mucositis in Adult Head & Neck Cancer Patients
The overall purpose of this clinical study is to evaluate safety and efficacy of the MuReva Phototherapy System with a light delivery mouthpiece to reduce the severity of oral mucositis (OM) in adult patients with squamous cell…
- Conditions
- Oral Mucositis (Ulcerative), Oral Mucositis (Ulcerative) Due to Radiation, Oral Mucositis (Ulcerative) Due to Antineoplastic Therapy, Head and Neck Cancer
- Trial name
- NCT03972527
- Testing
- Photobiomodulation, Routine Oral Care and Analgesia
- Where
- 12 sites in United States
- Volunteers
- 85 people
- Sponsor
- MuReva Phototherapy Inc.
Squamous Cell Carcinoma, Head and Neck Cancer
Study of Safety and Efficacy of Talimogene Laherparepvec With Cisplatin and Radiotherapy for Treatment of Locally Advanced Head and Neck Cancer
This study is being conducted to learn about the safety and risks of using talimogene laherparepvec to treat patients with head and neck cancer and to see if talimogene laherparepvec and chemoradiation together can destroy the…
- Trial name
- NCT01161498
- Testing
- Talimogene Laherparepvec, Radiation, Cisplatin
- Where
- 6 sites in United States, United Kingdom
- Volunteers
- 5 people
- Sponsor
- BioVex Limited
Radiation Proctitis
Evaluate the Distribution and Dynamic Behavior of Nuclide Labeled TH-SC01 Cells in Vivo in Patients With Radiation Proctitis
A Phase l clinical study evaluating the distribution and dynamic behavior of Nuclide labeled TH-SC01 cells in vivo in patients with Radiation proctitis
- Trial name
- NCT06925607
- Testing
- Mesenchymal Stem Cells (MSCs)
- Volunteers
- 6 people
- Sponsor
- Jiangsu Topcel-KH Pharmaceutical Co., Ltd.
Cutaneous Squamous Cell Carcinoma
Study of Adjuvant Cemiplimab Versus Placebo After Surgery and Radiation Therapy in Patients With High Risk Cutaneous Squamous Cell Carcinoma
The primary objective of the study is to compare disease-free survival (DFS) of patients with high-risk cutaneous squamous cell carcinoma (CSCC) treated with adjuvant cemiplimab, versus those treated with placebo, after surgery…
- Trial name
- NCT03969004
- Testing
- Cemiplimab
- Where
- 166 sites in United States, Australia and 14 more
- Volunteers
- 415 people
- Sponsor
- Regeneron Pharmaceuticals